Methods for the treatment of diabetes-associated dyslipdemia
AssigneeReddy US Therapeutics, Inc.
InventorsUday Saxena, Sivaram Pillarisetti, Ish Khanna
Life of this patent
Estimating the term…
Abstract
Methods for the treatment of insulin resistance, diabetes, and/or diabetes associated dyslipidemia by administering niacin and meloxicam are disclosed.
Claims11
A method of treating dyslipidemia in a subject having type 2 diabetes, the method comprising administering to the subject niacin in combination with meloxicam, wherein the meloxicam is administered in an amount that reduces niacin-induced insulin resistance in the subject.
A method of treating dyslipidemia in a subject having type 2 diabetes comprising administering to the subject niacin in combination with meloxicam and an anti-diabetic drug selected from the group consisting of rosiglitazone, pioglitazone, troglitazone, acarbose, migiltol, nateglinide, repaglinide, sitagliptin, pramlintide, metformin, and combinations thereof.
A method of treating dyslipidemia in a subject having type 2 diabetes, the method comprising administering to the subject niacin in combination with meloxicam, wherein the meloxicam is administered in an amount of from about 0.01 to about 1 mg/kg/day and the niacin is administered in an amount of from 1 to about 100 mg/kg/day.
A method of treating dyslipidemia in a subject having type 2 diabetes, the method comprising administering to the subject niacin in combination with meloxicam, wherein the meloxicam is administered in an amount of from about 0.1 to about 0.22 mg/kg/day and the niacin is administered in an amount of from about 7 to about 45 mg/kg/day.
Dependencies are inferred from the claim text.